Coronary disease & ACSRandomised controlled trial
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial
- Follow-up extension study of the BIOSTEMI randomised superiority trial
- investigator-initiated
- multicentre
- single-blind
- Bayesian
- 10 hospitals in Switzerland
Authors' conclusion
In patients undergoing primary percutaneous coronary intervention for STEMI, biodegradable polymer sirolimus-eluting stents were superior to durable polymer everolimus-eluting stents with respect to target lesion failure at 5 years of follow-up.
Study context
- Population
- Patients with STEMI undergoing primary PCI
- Participants
- 1,300 patients · 1,622 lesions
- Comparison
- Biodegradable polymer sirolimus-eluting stents vs durable polymer everolimus-eluting stents
- Biodegradable polymer sirolimus-eluting stentsn = 649
- Durable polymer everolimus-eluting stentsn = 651reference
- Primary endpoint
- Target lesion failure:
- Cardiac death
- Target vessel myocardial re-infarction
- Clinically indicated target lesion revascularisation
- Follow-up
- 5 years
Primary result
As reported in the abstract
Target lesion failure
BP-SES vs DP-EESRelative risk (95% CrI)
Bayesian CrI; posterior probability for superiority 0.988
0.70(0.51–0.95)
- Target lesion failure
- difference −3%
Original publication
Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet. Published 25 October 2023. doi:10.1016/s0140-6736(23)02197-9
Summarised from the published abstract; every number is checked against it